. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: Immunotherapy. 2011 Mar;3(3):435–441. doi: 10.2217/imt.10.111

Table 1.

Effect of T-bet deficiency in different autoimmune disease models.

Autoimmune disease/experimental model	Effect of T-bet deficiency
Autoimmune myasthenia gravis/EAMG	Decreased susceptibility
Autoimmune myocarditis/EAM	Exacerbation
Inflammatory bowel disease/AT-SCID/oxazolone-induced	Protection and increased susceptibility
Multiple sclerosis/EAE	Protection
Rheumatoid arthritis/CIA	Disease reduction
Type 1 diabetes/LCMV/NOD	Disease reduction and protection

AT-SCID: Adoptive transfer into SCID recipients (a mouse model for inflammatory bowel disease induced by adoptive transfer of CD4⁺CD62L⁺ cells to SCID mice); CIA: Collagen-induced arthritis model; EAE: Experimental autoimmune encephalomyelitis; EAM: Experimental autoimmune myocarditis; EAMG: Experimental autoimmune myasthenia gravis; LCMV: Lymphocytic choriomeningitis virus (a transgenic mouse model for virally induced Type 1 diabetes); NOD: Non-obese diabetic mouse model; SCID: Severe combined immunodeficiency.